A practical reference on melanogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
=== Hemostats === Hemostasis blood-staunching sponges for medical applications. They are used for injuries of the blood vessels to stop the bleeding for example during operations. Hemostats can be broken down by the body. For this reason, they remain in the body and the wound can stay closed.
Italian publication Everyeye retrospectively described Virtua Tennis as a "killer application" for the Dreamcast, noting the game's considerable commercial success. Gran Turismo 3 and the Grand Theft Auto games are the killer apps for the PlayStation 2. Star Wars Rogue Squadron II: Rogue Leader, Super Smash Bros. Melee, and Super Mario Sunshine are the killer apps for the GameCube. Halo: Combat Evolved, Halo 2, Project Gotham Racing and Dead or Alive 3 are the killer apps for the Xbox. The subsequent Halo series entries became killer apps for the Xbox 360 and Xbox One. Many video game and technology critics call Xbox Live a more general killer app for the Xbox. Dead or Alive 4, the Forza, Gears of War and Mass Effect series are also killer apps for the Xbox 360. Blue Dragon and Dead or Alive 4 were killer apps for the Xbox 360 in Japan. Wii Sports is the killer app for the Wii. Metal Gear Solid 4: Guns of the Patriots boosted PlayStation 3 sales. Mario Kart 8 is a killer app for the Wii U in the UK. The Legend of Zelda: Breath of the Wild is a killer app for the Nintendo Switch. Half-Life: Alyx is a killer app for virtual reality headsets, as the first true AAA virtual reality game. Sales of VR headsets such as the Valve Index increased dramatically after its announcement, suggesting users bought the product specifically for the game. Microsoft Flight Simulator was called a killer app for Xbox Game Studios's Xbox Game Pass subscription, and the Xbox Series X/S.
== Efficacy == Results from a Canadian double-blind, placebo-controlled biopsy Phase III clinical trial, involving total of 549 patients with diabetic sensorimotor polyneuropathy (DSP) randomly assigned to treatment with placebo or 10, 20, or 40 mg/day ranirestat for 52 weeks, showed that ranirestat appears to have effect on motor nerve function in mild to moderate DSP, but failed to show statistically significant difference in sensory nerve function. Efficacy of ranirestat was evaluated by nerve conduction studies, the modified Toronto Clinical Neuropathy Score (mTCNS), and quantitative sensory tests (QSTs).
=== Rett Syndrome === Missense mutations in the MeCP2 protein can cause Rett syndrome, otherwise known as the RTT phenotype. This phenotype primarily effects females, as males do not live with this mutation past infancy. T158M, R306C and R133C are the most common missense mutations causing RTT. T158M is a mutation of an adenine being substituted for a guanine causing the threonine at amino acid position 158 being substituted with a methionine. R133C is a mutation of a cytosine at base position 417 in the gene encoding the MeCP2 protein being substituted for a thymine, causing an amino acid substitution at position 133 in the protein of arginine with cysteine.
The Digico Micro 16V had a standard memory of 4k words with 950 nano second cycle time, expandable to 64k words, and able to support up to 64 external interfaces. It had an optional microprogrammed floating-point unit. The Micro 16V was supported by a simple and flexibly sized executive that could optionally support multiprogramming, disc files and teletypes. The Micro 16V used semiconductor memory, rather than magnetic-core memory as in the previous models. The instruction set architecture is single accumulator based with instructions generally having a consistent 12-bit address field. A direct address thus limits memory size to 4k (4096) words in the current selected memory region, named a "stack". Three instructions (load, store, add) permit indirect addressing where the direct address contains the 16-bit address of the operand. A carry register supports multi-word arithmetic; there is no integer multiply or divide instruction. One instruction uses the address field to specify a variety of non-addressing sub-instructions such as shift, carry manipulation and input-output. Floating-point arithmetic is handled by software or an optional floating-point unit with its own registers that can work in 32, 48 or 80-bit modes. The Micro 16 sold primarily into the data logging market until 1969, when it expanded into areas like process control, stock control and front-end processors for the ICL 1900 mainframe. In 1978 the Digico Micro 16E stackable minicomputer, which was well suited to an office environment, won a Design Council Award for Engineering Products.
Sources: en.wikipedia.org
== Agricultural use == In the United States, it is legal to give a bovine GH to dairy cows to increase milk production, and is legal to use GH in raising cows for beef; see article on Bovine somatotropin, cattle feeding, dairy farming and the beef hormone controversy. The use of GH in poultry farming is illegal in the United States. Similarly, no chicken meat for sale in Australia is administered hormones. Several companies have attempted to have a version of GH for use in pigs (porcine somatotropin) approved by the FDA but all applications have been withdrawn.
==== Prison overcrowding ==== One consequence of the war on drugs policy has been the overcrowding of American prisons. The policy's approach to prosecuting drug-related crimes led to a surge in incarcerated individuals for nonviolent drug offenses. As a result, many prisons have become overburdened, often operating at capacities far beyond their intended limits. Overcrowding strains the prison system and raises questions about the effectiveness of incarceration as a solution to drug-related issues. Resources that could be allocated to address the root causes of drug abuse, provide rehabilitation and treatment programs, or support communities affected by drug-related issues, are instead used to manage the considerable prison population. Critics argue that focusing solely on incarceration fails to address the underlying social factors contributing to drug abuse and perpetuates a cycle of criminality without offering pathways to recovery and reintegration into society.
=== Cancer === In a 2024 retrospective study, GLP-1 exposure was associated with a lower risk of specific obesity-associated cancers compared with insulin or metformin among people with type 2 diabetes. Compared to insulin, GLP-1 agonists showed significant risk reduction in esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, as well as meningioma and multiple myeloma. Kidney cancers showed an increased risk with GLP-1 treatment relative to those treated with metformin.
Glycine and proline are strongly present within low complexity regions of both eukaryotic and prokaryotic proteins, whereas the opposite is the case with cysteine, phenylalanine, tryptophan, methionine, valine, leucine, isoleucine, which are highly reactive, or complex, or hydrophobic. Many proteins undergo a range of posttranslational modifications, whereby additional chemical groups are attached to the amino acid residue side chains sometimes producing lipoproteins (that are hydrophobic), or glycoproteins (that are hydrophilic) allowing the protein to attach temporarily to a membrane. For example, a signaling protein can attach and then detach from a cell membrane, because it contains cysteine residues that can have the fatty acid palmitic acid added to them and subsequently removed.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.